# EDGAR Filing Document

**Accession Number:** 0001680367
**File Stem:** 0001104659-26-073086
**Filing Date:** 2026-6
**Character Count:** 15273
**Document Hash:** b4062b44d1fb26e98db738fa360cbf4d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-073086.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001104659-26-073086

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shattuck Labs, Inc.
- **CENTRAL INDEX KEY:** 0001680367
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812575858
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91760
- **FILM NUMBER:** 261084743

**BUSINESS ADDRESS:**
- **STREET 1:** 500 W. 5TH STREET
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
- **BUSINESS PHONE:** 512-900-4690

**MAIL ADDRESS:**
- **STREET 1:** 500 W. 5TH STREET
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78701
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Redmile Group, LLC
- **CENTRAL INDEX KEY:** 0001425738

**ORGANIZATION NAME:**
- **EIN:** 208592298
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE
- **STREET 2:** SUITE 270
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939
- **BUSINESS PHONE:** 415-489-9980

**MAIL ADDRESS:**
- **STREET 1:** 900 LARKSPUR LANDING CIRCLE
- **STREET 2:** SUITE 270
- **CITY:** LARKSPUR
- **STATE:** CA
- **ZIP:** 94939

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Shattuck Labs, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Redmile Group, LLC**<br>Attn: Josh Garcia<br>900 Larkspur Landing Circle, Suite 270<br>Larkspur CA 94939<br>(415) 489-9980

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/09/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Redmile Group, LLC** | Name of reporting person<br>**Redmile Group, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9819084.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9819084.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9819084.00** | Aggregate amount beneficially owned by each reporting person<br>**9819084.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** (1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"), including Redmile Biopharma Investments II, L.P. ("RBI II").

(2) The information in Item 5(a) relating to the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") and the calculation of the beneficial ownership percentage of such class of securities is incorporated by reference herein.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jeremy C. Green** | Name of reporting person<br>**Jeremy C. Green** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9819084.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9819084.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9819084.00** | Aggregate amount beneficially owned by each reporting person<br>**9819084.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The source of funds was working capital of the Redmile Funds, including RBI II.

(2) The information in Item 5(a) relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green and the calculation of the beneficial ownership percentage of such class of securities is incorporated by reference herein.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Redmile Biopharma Investments II, L.P.** | Name of reporting person<br>**Redmile Biopharma Investments II, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6119962.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6119962.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6119962.00** | Aggregate amount beneficially owned by each reporting person<br>**6119962.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.2%** | Percent of class represented by amount in Row (11)<br>**6.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** (1) The information in Item 5(a) relating to the shares of Common Stock that are or may be deemed beneficially owned by RBI II and the calculation of the beneficial ownership percentage of such class of securities is incorporated by reference herein.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Shattuck Labs, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
500 W. 5th Street, Suite 1200, Austin, TX, 78701

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprised of (i) 7,038,119 shares of Common Stock held by the Redmile Funds, including the 3,338,997 shares of Common Stock directly held by RBI II, and (ii) subject to the 9.99% beneficial ownership limitation (the "Beneficial Ownership Limitation"), 10,943,951 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, including the 5,647,258 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants directly held by RBI II. The 2,780,965 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants reported as beneficially owned by the Reporting Persons represent the maximum number of shares of Common Stock that could be issued upon exercise of those Pre-Funded Warrants subject to the Beneficial Ownership Limitation. All of the reported securities are directly owned by certain Redmile Funds. Redmile may be deemed to beneficially own these securities in its capacity as the investment manager of the Redmile Funds with discretion to vote and dispose of their portfolio securities. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of the reported securities, except to the extent of its or his pecuniary interest in such securities, if any.

Redmile and Mr. Green may be deemed to beneficially own 146,086 shares of Common Stock subject to options to purchase shares of Common Stock that are exercisable within 60 days of the date of this filing, and such amount is included in the number disclosed in (i) above. The stock options were granted to Mike Lee, a managing director of Redmile, in connection with his former service as a member of the Board of Directors, which ceased on August 25, 2025. Pursuant to the policies of Redmile, Mr. Lee holds the stock options as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock options to Redmile.

Percentage for each Reporting Person based on sum of: (i) 95,508,165 shares of Common Stock outstanding immediately after the Underwritten Offering (including the exercise of the underwriters' option to purchase additional shares of Common Stock), as reported by the Issuer in its Prospectus Supplement to the Prospectus dated January 21, 2026, which was filed with the Securities and Exchange Commission on June 11, 2026, plus (ii) 2,780,965 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants directly held by the Redmile Funds (including RBI II), which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.

**(b)**
Item 5(b) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

Redmile:

(1) Sole Voting Power: 0
(2) Shared Voting Power: 9,819,084
(3) Sole Dispositive Power: 0
(4) Shared Dispositive Power: 9,819,084

Jeremy C. Green:

(1) Sole Voting Power: 0
(2) Shared Voting Power: 9,819,084
(3) Sole Dispositive Power: 0
(4) Shared Dispositive Power: 9,819,084

RBI II:

(1) Sole Voting Power: 0
(2) Shared Voting Power: 6,119,962
(3) Sole Dispositive Power: 0
(4) Shared Dispositive Power: 6,119,962

**(c)**
See the response to Item 3. Except as disclosed in Item 3, no reportable transactions were effected by any Reporting Persons during the past sixty days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Prior Schedule 13D is hereby amended and supplemented in its entirety by adding the following paragraphs prior to the last paragraph of Item 6:

Pre-Funded Warrants to Purchase Common Stock

Pre-Funded Warrants were acquired by the Redmile Funds, not including RBI II, in the Underwritten Offering at a price of $3.9999 per Pre-Funded Warrant and entitle the holder to purchase up to an aggregate of 1,000,000 shares of Common Stock, subject to the Beneficial Ownership Blocker, at an exercise price of $0.0001 per Pre-Funded Warrant. The Pre-Funded Warrants are exercisable by the holder at any time on or after the issuance date until fully exercised.

The foregoing summary of the Pre-Funded Warrants is not intended to be complete and is qualified in its entirety by reference to the full text of the Form of Pre-Funded Warrant, which is filed as Exhibit 99.12 to this Schedule 13D and is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Redmile Group, LLC

**Signature:** /s/ Jeremy C. Green

**Name/Title:** Managing Member

**Date:** 06/11/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jeremy C. Green

**Signature:** /s/ Jeremy C. Green

**Name/Title:** Jeremy C. Green

**Date:** 06/11/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Redmile Biopharma Investments II, L.P.

**Signature:** /s/ Jeremy C. Green

**Name/Title:** Managing Member of Redmile Biopharma Investments II (GP), LLC, general partner of Redmile Biopharma Investments II, L.P.

**Date:** 06/11/2026